Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

View our complete analysis and fair value estimate and you decide. NasdaqGS:DXCM Earnings Per Share Growth as at Mar 2025 AI is about to change healthcare. These 23 stocks are working on ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

The company response is inadequate. DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...